KZIA

NASDAQ

Kazia Therapeutics Limited

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations

News25/Ratings3

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

News · 26 weeks72+109%

2025-10-262026-04-19

Mix4290d

SEC Filings27(64%)
Insider7(17%)
Other6(14%)
Leadership1(2%)
Analyst1(2%)

Latest news

25 items

8dSEC
SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
8dSEC
SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
8dSEC
SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
8dSEC
SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
8dSEC
SEC Form 6-K filed by Kazia Therapeutics Limited
6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
8dANALYST
Laidlaw initiated coverage on Kazia Therapeutics with a new price target
Laidlaw initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $25.00
8dPR
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the appointment of Dr. Sudha Rao as Chief Scientific Officer (CSO). Dr. Rao is the scientific originator of the epigenetic framework underlying paxalisib and a pioneer in next-generation therapeutic platforms, including PD-L1 protein degradation and SETDB1-targeted chromatin modulation. Her appointment brings deep expertise in translational epigenetics, AI-guided epi-drug discovery capability, liquid and spatial epigenetic clinical biomarker precision medicine platforms, and early clinical development
10dSEC
SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
10dSEC
SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
10dSEC
SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
10dSEC
SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
10dSEC
SEC Form 6-K filed by Kazia Therapeutics Limited
6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
10dPR
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
SYDNEY, Australia, April 13, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The platform includes use of an AI-integrated epigenetic drug discovery engine, enabling rapid, precise, and scalable candidate generation. The lead drug candidate, MSETC, was discovered and optimized using this AI-integrated epigenetic drug discovery engine. MSETC is a highly selective bicyclic peptide designed to target a novel, disease-associated nuclear SETDB1 com
14dINSIDER
Amendment: SEC Form 3 filed by new insider Friend John E. Ii
3/A - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
22dINSIDER
SEC Form 3 filed by new insider Cain David
3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
23dSEC
SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
23dSEC
SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
23dSEC
SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
23dSEC
SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
23dSEC
SEC Form 6-K filed by Kazia Therapeutics Limited
6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
23dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Kazia Therapeutics Limited
SCHEDULE 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
24dSEC
SEC Form 6-K filed by Kazia Therapeutics Limited
6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
25dSEC
SEC Form EFFECT filed by Kazia Therapeutics Limited
EFFECT - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
35dSEC
SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
35dSEC
SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)